Renin–angiotensin–aldosterone system inhibitors are the cornerstone therapy for attenuating the progression of CKD to end-stage renal disease (ESRD) because they aim to lowering the intraglomerular pressure-mediated injury, a well-recognized mechanism for structural damage in CKD progression; however, the effect is moderate (Zhong et al., 2013). Here, REN is linked to chronic kidney disease.